7.90
price up icon3.54%   0.27
pre-market  Pre-mercato:  7.97   0.07   +0.89%
loading
Precedente Chiudi:
$7.63
Aprire:
$7.64
Volume 24 ore:
1.98M
Relative Volume:
0.75
Capitalizzazione di mercato:
$570.79M
Reddito:
$161.10M
Utile/perdita netta:
$-308.60M
Rapporto P/E:
-1.6916
EPS:
-4.67
Flusso di cassa netto:
$-259.90M
1 W Prestazione:
+1.28%
1M Prestazione:
+7.78%
6M Prestazione:
-58.18%
1 anno Prestazione:
-68.21%
Intervallo 1D:
Value
$7.53
$8.11
Intervallo di 1 settimana:
Value
$7.30
$8.11
Portata 52W:
Value
$5.90
$34.11

Arvinas Inc Stock (ARVN) Company Profile

Name
Nome
Arvinas Inc
Name
Telefono
203-535-1456
Name
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Name
Dipendente
430
Name
Cinguettio
@ArvinasInc
Name
Prossima data di guadagno
2025-02-11
Name
Ultimi documenti SEC
Name
ARVN's Discussions on Twitter

Confronta ARVN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ARVN
Arvinas Inc
7.90 570.79M 161.10M -308.60M -259.90M -4.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Arvinas Inc Stock (ARVN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-02 Downgrade Leerink Partners Outperform → Market Perform
2025-05-05 Downgrade Truist Buy → Hold
2025-05-02 Downgrade Jefferies Buy → Hold
2025-05-02 Downgrade TD Cowen Buy → Hold
2025-03-13 Downgrade Goldman Buy → Neutral
2025-03-12 Downgrade Wedbush Outperform → Neutral
2025-03-11 Downgrade Oppenheimer Outperform → Perform
2024-12-10 Iniziato BTIG Research Buy
2024-11-18 Iniziato Stephens Overweight
2024-02-28 Reiterato Oppenheimer Outperform
2024-02-14 Downgrade Citigroup Buy → Neutral
2024-02-01 Iniziato Goldman Buy
2023-12-19 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-12-06 Aggiornamento Jefferies Hold → Buy
2023-11-20 Aggiornamento Guggenheim Neutral → Buy
2023-10-23 Aggiornamento Wedbush Neutral → Outperform
2023-06-26 Ripresa Oppenheimer Outperform
2023-01-12 Downgrade Guggenheim Buy → Neutral
2023-01-03 Downgrade Wells Fargo Overweight → Equal Weight
2022-09-09 Iniziato Barclays Overweight
2022-06-21 Iniziato Jefferies Hold
2022-05-09 Downgrade Wedbush Outperform → Neutral
2022-04-28 Iniziato Credit Suisse Outperform
2022-04-06 Iniziato Morgan Stanley Equal-Weight
2022-02-11 Ripresa BMO Capital Markets Outperform
2022-02-10 Iniziato Wells Fargo Overweight
2022-01-19 Iniziato Goldman Buy
2021-12-07 Iniziato Cowen Outperform
2021-10-14 Iniziato SVB Leerink Outperform
2021-09-30 Iniziato Stifel Buy
2021-09-09 Iniziato BofA Securities Buy
2021-05-21 Iniziato UBS Buy
2021-04-21 Iniziato Truist Buy
2021-03-31 Iniziato BMO Capital Markets Outperform
2020-12-14 Aggiornamento Oppenheimer Perform → Outperform
2020-06-01 Aggiornamento Citigroup Neutral → Buy
2020-05-12 Iniziato Oppenheimer Perform
2019-12-19 Iniziato H.C. Wainwright Buy
2019-11-25 Iniziato Guggenheim Buy
2019-10-24 Aggiornamento Goldman Neutral → Buy
2019-09-25 Iniziato Wedbush Outperform
2019-09-12 Iniziato BMO Capital Markets Outperform
2019-08-06 Iniziato Cantor Fitzgerald Overweight
2019-06-05 Downgrade Citigroup Buy → Neutral
2019-04-12 Iniziato Evercore ISI Outperform
2018-10-22 Iniziato Citigroup Buy
2018-10-22 Iniziato Goldman Neutral
2018-10-22 Iniziato Piper Jaffray Overweight
Mostra tutto

Arvinas Inc Borsa (ARVN) Ultime notizie

pulisher
Jun 18, 2025

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga

Jun 18, 2025
pulisher
Jun 17, 2025

Logos Global Management LP Acquires 4,800,000 Shares in Arvinas Inc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Arvinas (NASDAQ:ARVN) Shares Gap UpWhat's Next? - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Logos Global Management LP Issues a Letter to the Board of Arvinas, Inc. - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade - MSN

Jun 17, 2025
pulisher
Jun 14, 2025

Arvinas’s SWOT analysis: vepdegestrant efficacy fuels stock potential amid market challenges - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

Analysts Set Expectations for Arvinas FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

ARVN: Arvinas' ARV-393 Shows Promise in Preclinical Lymphoma Stu - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV- - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Arvinas Unveils Promising ARV-393 Data at EHA Congress - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, - GlobeNewswire

Jun 13, 2025
pulisher
Jun 13, 2025

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - GlobeNewswire Inc.

Jun 13, 2025
pulisher
Jun 09, 2025

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

Arvinas (NASDAQ:ARVN) Stock Price Up 8.7%Here's Why - MarketBeat

Jun 09, 2025
pulisher
Jun 08, 2025

Wedbush Predicts Arvinas' FY2026 Earnings (NASDAQ:ARVN) - MarketBeat

Jun 08, 2025
pulisher
Jun 08, 2025

Wellington Management Group LLP Has $570,000 Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - WV News

Jun 07, 2025
pulisher
Jun 07, 2025

Leerink Partnrs Has Strong Estimate for Arvinas Q2 Earnings - MarketBeat

Jun 07, 2025
pulisher
Jun 07, 2025

Arvinas (NASDAQ:ARVN) Shares Gap DownHere's Why - MarketBeat

Jun 07, 2025
pulisher
Jun 06, 2025

Arvinas and Pfizer seek FDA approval for breast cancer drug By Investing.com - Investing.com South Africa

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas (NASDAQ:ARVN) Stock Rating Lowered by Leerink Partnrs - MarketBeat

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas R&D President Ian Taylor Resigns - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas (ARVN) and Pfizer Submit NDA for Breast Cancer Treatment - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas Announces Submission of New Drug Application to U.S. FDA - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment? - insights.citeline.com

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas (ARVN) and Pfizer Submit FDA Application for Breast Canc - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Pfizer, Arvinas seek FDA nod for breast cancer therapy (ARVN) - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas stock rises on FDA submission with Pfizer By Investing.com - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas stock rises on FDA submission with Pfizer - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas and Pfizer seek FDA approval for breast cancer drug - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas announces submission of NDA to FDA for vepdegestrant - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas, Pfizer Submit New Drug Application for Vepdegestrant as Breast Cancer Treatment - marketscreener.com

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas (ARVN) and Pfizer Submit NDA for Breast Cancer Treatment | ARVN Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer - marketscreener.com

Jun 06, 2025
pulisher
Jun 06, 2025

Arvinas Announces Submission of New Drug Application to - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

What is Wedbush’s Forecast for Arvinas FY2026 Earnings? - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Q2 Earnings Forecast for Arvinas Issued By Leerink Partnrs - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, AR - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting | ARVN Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Arvinas, Inc. to Present Preclinical Data on ARV-393, an Investigational PROTAC BCL6 Degrader, at EHA Meeting 2025 - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

Arvinas to Present Preclinical Data for PROTAC BCL6 - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Breakthrough PROTAC Technology Shows Efficacy Against 3 Types of Aggressive Lymphoma - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

Arvinas (NASDAQ:ARVN) Earns Market Perform Rating from Leerink Partners - MarketBeat

Jun 05, 2025
pulisher
Jun 05, 2025

Bank of America Corp DE Has $2.47 Million Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat

Jun 05, 2025
pulisher
Jun 03, 2025

H.C. Wainwright reaffirms buy rating on Arvinas stock after trial data - Investing.com Nigeria

Jun 03, 2025
pulisher
Jun 03, 2025

Voloridge Investment Management LLC Buys Shares of 39,063 Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat

Jun 03, 2025

Arvinas Inc Azioni (ARVN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):